PTAB Upholds Testing Patents After Ravgen's $272M Jury Win
The Patent Trial and Appeal Board has rebuffed biotechnology company Illumina's bid to ax two genetic testing patents that have been asserted against it and others by rival Ravgen in federal...To view the full article, register now.
Already a subscriber? Click here to view full article